Press Releases April 27, 2026 09:00 AM

Nasdaq Resumes Trading in American Rebel Holdings, Inc.

Nasdaq resumes trading of American Rebel Holdings stock after over a month-long halt

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
AREB

Nasdaq announced the resumption of trading for American Rebel Holdings, Inc. (AREB and AREBW) on April 27, 2026, after the trading halt that began on March 20, 2026. Investors can now buy and sell the company's stock and warrants again on the Nasdaq exchange.

Nasdaq Resumes Trading in American Rebel Holdings, Inc.
AREB
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Trading of American Rebel Holdings' stock and warrants was halted on March 20, 2026.
  • Trading resumed on April 27, 2026, at 11:00 a.m. Eastern Time on Nasdaq.
  • Investors are encouraged to check the Nasdaq website or contact the company for further information.

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading will resume in American Rebel Holdings, Inc. (Nasdaq: AREB and AREBW) at 11:00 a.m. Eastern Time on April 27, 2026. Trading in the company’s stock and warrants was halted on March 20, 2026 at 7:50pm Eastern Time.

For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.

Nasdaq Contact:

Nasdaq MarketWatch
dl-NasdaqMarketWatch@nasdaq.com

NDAQO


Risks

  • The reasons for the previous trading halt are not stated, potentially indicating underlying uncertainties.
  • Resumption of trading after a halt can increase volatility and investor uncertainty.
  • Potential regulatory or company-specific issues that led to the halt could still impact stock performance.

More from Press Releases

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026